18:23 , Nov 9, 2018 |  BC Week In Review  |  Company News

Abeona gets rights to RegenxBio gene therapy vector

Gene therapy company RegenxBio Inc. (NASDAQ:RGNX) granted Abeona Therapeutics Inc. (NASDAQ:ABEO) exclusive, worldwide rights to use RegenxBio's NAV adeno-associated virus 9 (AAV9) vector to develop therapies for four lysosomal storage disorders. Abeona will pay RegenxBio...
16:34 , Sep 21, 2018 |  BC Week In Review  |  Company News

Celenex takeout first of several expected Amicus gene therapy deals

Just weeks after gaining its first FDA approval, Amicus Therapeutics Inc. (NASDAQ:FOLD) has announced its entrance into the gene therapy space with the acquisition of Nationwide Children's Hospital spinout Celenex (Columbus, Ohio) for $100 million...
23:14 , Sep 20, 2018 |  BC Extra  |  Company News

Celenex takeout first of several planned gene therapy deals for Amicus

Just weeks after gaining its first FDA approval, Amicus Therapeutics Inc. (NASDAQ:FOLD) has announced its entrance into the gene therapy space with the acquisition of Nationwide Children's Hospital spinout Celenex (Columbus, Ohio) for $100 million...
08:00 , Dec 10, 2015 |  BC Innovations  |  Product R&D

Spark in the brain

Spark Therapeutics Inc. is expanding beyond eye and blood diseases with its first foray into the brain for the rare neuronal disorder Batten disease, using a gene therapy delivered to the ependymal cells in the...
07:00 , Jul 20, 2015 |  BC Week In Review  |  Company News

Abeona Therapeutics, University of Nebraska deal

The UNeMed Corp. tech transfer arm of the university’s medical center granted Abeona exclusive, worldwide rights to develop and commercialize ABO-201 to treat juvenile Batten disease. The parties declined to provide financial details. ABO-201, an...